| Revenue growth | 23.6% INR growth; 18.2% USD growth for FY26. |
|---|---|
| Margins | Temporary 150bps impact from investments; recovery expected by H2FY27. |
| Order book | Closed 8 major ACV deals in Q4 including $3M+ clinical win. |
| Demand visibility | Strong pipeline entering FY27; high adoption of AI-led mandates. |
| Management confidence | High; transitioning from 'cautiously optimistic' to 'excited and confident'. |
Growth
FY26 revenue up 23.6% to ₹35,105M; Q4 adjusted EBITDA grew 23.2% YoY to ₹1,889M.
Outlook
Expects EBITDA margins to revert to historical highs in H2FY27; no formal revenue guidance provided.
Risks
Legal provision of ₹203M for US TCPA lawsuit; currency volatility impacting unexpired forward contracts.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹605.45
- Market cap
- ₹14,586 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.4×Sector 53.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Legal & Regulatory
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
Indegene Legal & Regulatory
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
- Value
- ₹45.24 Cr